Living medicines built from genetically modified bacteria have long promised to sense disease, produce drugs on demand, and vanish when their work is done. A comprehensive new review in Frontiers in ...
An open-label pilot trial found that a single fecal microbiota transplantation cleared adherent-invasive E. coli from the gut ...
WashU Medicine researchers have been awarded a nearly $11 million grant from the National Institute of Allergy and Infectious ...
The View from the Examination RoomIn New York, I was collecting stool samples.To be precise, I was using genetic analysis to ...
A 2025 survey of NHS employees highlighted worrying variations in awareness of C difficile infection, risk factors and ...
Resplice Autism Research Foundation & Institute has opened its second Faecal Microbiota Transplantation (FMT) Centre in India ...
An antibiotic resistance gene helps a dangerous gut bacterium build tougher spores that can survive hospital disinfectants.
These findings provide new clinical evidence that LANCL2 activation may address inflammatory, metabolic and fibrotic processes associated with treatment refractoriness in IBD patients and support the ...
Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota® and Clenpiq®, two established FDA-approved gastrointestinal (GI) ...
The pathogen Clostridioides difficile (C. difficile) is naturally present in the intestines of many people. When present in ...
Acurx Pharmaceuticals (ISIN US00510M2035) remains tied to a USD 10.00 analyst target after Stock Analysis reported on ...
Monthly long-form interviews will air on Bloomberg Television across four regions and on New to The Street TV's YouTube ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results